Pregnancy & Newborn Screening Developments. What is screening? Screening is: “a public health service in which members of a defined population, who do.

Slides:



Advertisements
Similar presentations
Newborn Screening in Texas Jann Melton-Kissel Susan U. Neill.
Advertisements

Implementing NICE guidance
Implementing NICE guidance
Day 2 You receive 2 reports on your desk –The first describes the possibility of expanding the states newborn screening panel to include Severe Combined.
Cystic Fibrosis BY. MERCEDES.
Genetics and genomics for healthcare © 2012 NHS National Genetics Education and Development Centre Genetic testing: What is.
Antenatal Screening Dr Emma Parry CMFM
Screening programmes Practice nurse forum 13 th January 2009.
Antenatal Screening Mehreen Yousaf GP STS.
Treuman Katz Center for Pediatric Bioethics Conference Newborn Screening: The Future Revolution Beth A. Tarini, MD, MS Assistant Professor Child.
Newborn Screening Overview Marie Mann, M.D., M.P.H. U.S. Department of Health and Human Services Health Resources and Services Administration Maternal.
Pregnancy & Newborn Screening Developments
Prepared by Jane Hibbert on behalf of the Regional ANCH Screening Teams Expanded Newborn Screening Pilot 16th July 2012 – 19th July 2013 NIHR CLAHRC for.
August 2006 Newborn Screening Programmes. Introduction These slides bring you up to date with the three NSC Newborn Screening Programmes The Blood Spot.
NHS Blood Spot Screening Programme Marie Coughlin Screening Lead July 26 th 2010.
Genetic screening.
Chapter 11 Newborn Screening. Introduction Newborns can be screened for an increasing variety of conditions on the principle that early detection can.
Pregnancy & Newborn Screening Developments
Genetic Screening for Cystic Fibrosis A New Choice for You and Your pregnancy.
Screening PHIL THIRKELL. What is screening?  A process of identifying apparently healthy people who may be at risk of a disease or condition  Identify.
Genetic Testing Make a list of all the genetic tests babies get (you will probably have had these!)
North West London Haemoglobinopathy Managed Clinical Network Lola Oni Professional Services Director/ Lecturer Brent Sickle Cell & Thalassaemia Centre.
Anndrea Kelly Erika Dye. What is Genetic Counseling? evaluating family history and medical records ordering genetic tests evaluating the results of this.
Pregnancy & Newborn Screening Developments Medium Chain Acyl CoA Dehydrogenase Deficiency (MCADD)
xt xt5629 Neo-natal screening in North London David Bowen Ken Smith Great Ormond.
Pregnancy Screening Pathway
Newborn screening (NBS) is a simple procedure to find out if your baby has a congenital metabolic disorder that may lead to mental retardation and even.
Pregnancy & Newborn Screening Developments
9/7/2015Mahia Samaha Alkony1 Genetics By: Mrs. Mahdiah Samaha Alkony.
Sex linked genes.
Problems in Prenatal Development
Phenylketonuria (PKU) By: Greg Ancmon and Brennan Ramos Period 2.
Jshmay09 Laboratory Perspective of screening Joan Henthorn Central Middlesex Hospital London UK July 2009.
THE ANSWERS. What is this? A silver replica of a Van Leeuwenhoek microscope.
Newborn Screening in Wisconsin Jill Paradowski RN, MS Newborn Screening Coordinator Southeast region of Wisconsin.
Case Study #1 You are an Army officer during the Korean War, and are in charge of a group of soldiers preparing to deploy from Fort Dix, New Jersey. In.
NHS Sickle Cell and Thalassaemia Screening Programme sct.screening.nhs.uksct.screening.nhs.uk NHS Sickle Cell and Thalassaemia Screening Programme Allison.
ACB Training Course- Plymouth Down’s syndrome screening David Worthington (Laboratory Advisor - National Screening Programme)
Screening Puja Myles
1 Stimulating Systems Change for Fetal Alcohol Spectrum Disorder (FASD) Canadian Public Health Association Conference June 2, 2008.
The Scottish Newborn Screening Laboratory (SNSL) Dr David Aitken Laboratory Director Pregnancy and Newborn Screening Institute of Medical Genetics Yorkhill,
Implementing Haemoglobinopathy Screening in Scotland Summary of screening, laboratory and clinical service mapping exercise May 2009.
Women’s Health Evening Portishead Medical Group Monday 12 th October pm.
The Role of Prenatal screening as part of Routine Obstetric Care
NHS Fetal Anomaly Screening Programme Marie Coughlin Screening Lead January 25 th 2010.
TEXAS NEWBORN SCREEN PRESENTED BY: SHAYNA BAUMAN & ROSA CARRANZA UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON ADVANCED NEONATAL HEALTH ASSESSMENT GNRS.
Newborn screening Doc. MUDr. Marie Černá, CSc. Lecture No 423-H.
Many hundred disorders resulting from this type of inheritance are known An affected individual is homozygous for the abnormal gene, having inherited an.
1 Chapter 6: Non-Communicable Diseases. 2 Impact of Non- Communicable Diseases These chronic diseases drive healthcare costs at an alarming annual rate:
Haemoglobinopathy testing and screening Dr Susan Baird Consultant Paediatric Haematologist RHSC Edinburgh.
NEWBORN SCREENING SAVE YOUR BABY from MENTAL RETARDATION ZHALLENE MICHELLE E. SANCHEZ.
NEWBORN BLOODSPOT - IMPROVING PRACTICE. Screening Tests Offered from 4 th Oct 2010: Phenylketonuria (PKU) Congenital Hypothyroidism (CHT)
The Scottish Woman-Held Maternity Record (SWHMR) Version 4, January 2008.
Croydon Health Services
NHS Antenatal and Newborn Screening Programmes: Key Messages 2016/17
Autosomal recessive inheritance
primary and secondary use of dried blood spots
Detection of heterozygotes
What to screen for and when? 18th January 2014 PACITA Lisbon
Tests During Pregnancy
Higher Human Biology Subtopic 12 Ante and postnatal screening
Genetic Testing Result Means. Before Genetic Testing  The result of genetic testing can be life changing.  It is important for patients and their families.
NEWBORN SCREENING IN THE UK
Genetic Testing.
Newborn Bloodspot Screening: bringing it under the Screening Umbrella
guidance on antenatal screening
Haemoglobinopathy testing and screening

Key Area 2.4 – Ante- and Post-natal Screening
NHS Sickle Cell & Thalassaemia Screening Programme
Presentation transcript:

Pregnancy & Newborn Screening Developments

What is screening? Screening is: “a public health service in which members of a defined population, who do not necessarily perceive they are at risk of, or are already affected by, a disease or its complications, are asked a question or offered a test to identify those individuals who are more likely to be helped than harmed by further tests or treatment to reduce the risk of disease or its complications.” (Second Report of the UK National Screening Committee)

CEL 31 (2008) Changes to the pregnancy and newborn screening programmes The replacement of the existing Pregnancy Screening Programme offered for Down’s Syndrome and other congenital anomalies The introduction of haemoglobinopathy screening during pregnancy and sickle cell screening for newborn babies The extension of the newborn blood spot screening programme to include screening for Medium Chain Acyl CoA Dehydrogenase Deficiency (MCADD).

Implementation CEL 31 – no later than 31 st March 2011 Newborn blood spot changes – 4 th October 2010 Pregnancy screening changes - 4 th October – end February 2011

National Services Division to lead, co-ordinate and support NHS Boards in making the changes. Additional funding allocated for: – Implementation of the development required in the pregnancy screening laboratories. – Commissioning the Scottish newborn screening laboratory to introduce sickle cell and MCADD screening into the newborn bloodspot screening programme.

First Trimester Screening for Down’s syndrome Combination of 2 serum markers (PAPP-A, FßhCG) and NT measurement – weeks gestation Improved detection rate – 90% Second trimester screening test available for women too late for 1 st Trimester (Quadruple test)

Antenatal Haemoglobinopathy Screening No haemoglobinopathy is exclusive to any single ethnic group and all people are theoretically at risk Importance of early testing – link to KCND key messages Training required for haematology lab staff Importance of FOQ Need for further counselling and partner testing Co-ordination of screening essential

Family Origin Questionnaire FOQ Categories may be used in paper format or electronically Use is endorsed by NICE Information from both the woman and the baby’s father are required

Screening Tests from 4 th Oct 2010: Phenylketonuria (PKU) Congenital Hypothyroidism (CHT) Cystic Fibrosis (CF) – 2003 Medium Chain Medium chain CoA Dehydrogenase Deficiency (MCADD) Sickle Cell Disorders (SCD)

NEW CARD Use new card (BLUE) All old cards (PINK) must be destroyed or returned to the laboratory.

Newborn Sickle Cell Screening Affects 1 in 2,500 babies in UK Inherited condition Causes pain, tissue damage, infection and even death Allows early diagnosis, improved outcomes through early treatment and care Need for pre-transfusion sample on admission to neonatal unit Carriers will be identified

Linked Pregnancy & Newborn Programme Vital for Scottish Newborn Screening Laboratory to know parents carrier status – therefore record on blood spot card Testing babies born to at-risk couples Important to know parents’ carrier status when dealing with newborn results

MCADD Medium Chain Acyl-CoA Dehydrogenase Deficiency Caused by the lack of an enzyme (‘catalyst’) required to convert stored fat to energy Affects 1 in 10,000 babies born in the UK In Scotland screening should identify 5 – 10 cases a year

Why screen for MCADD Early identification results in early treatment reducing risk of acute life threatening episodes Early detection of MCADD allows crisis/sudden death to be avoided Adherence to dietary management - normal life can be expected

Revised Leaflets

Useful Links Join the Pregnancy & Newborn Screening Network community For further information on education & training contact Lucy Powls, Project Lead (Pregnancy & Newborn Screening) at